TerminatedPhase 3

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Stopped: Due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators

China36 participantsStarted 2021-03-10

Plain-language summary

The main purpose of this study is to evaluate the efficacy and safety of sintilimab plus ramucirumab compared to stand of care first-line chemotherapy in participants with advanced gastric or esophagogastric adenocarcinoma.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria * Have a histologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma * With HER2 negative and PD-L1 positive tumor tissue * Have fresh or archival tumor tissue samples within 6 months for PD-L1 expression test. * Age ≥18 and ≤75 years * Diagnosed as unresectable locally advanced or metastatic stage Exclusion criteria * Have received any prior palliative systemic treatment for advanced gastric or gastroesophageal junction adenocarcinoma. * Known to have central nervous system metastases, cancerous meningitis, or bone metastases with a risk of paraplegia * Known bone metastasis with a risk of paraplegia. * Have any ascites that requires intervention. * With bilateral medium pleural effusion or unilateral large pleural effusion leading to respiratory symptoms

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Safety and tolerability of sintilimab plus ramucirumab,Overall survival (OS)

Timeframe: Randomization to Death from Any Cause, up to 60 months

Trial details

NCT IDNCT04675983

SponsorInnovent Biologics (Suzhou) Co. Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-02-12

View on ClinicalTrials.gov More Gastric Adenocarcinoma trials

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.